search
Back to results

Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?

Primary Purpose

PreDiabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Flaxseed High Dose
Flaxseed Low Dose
Sponsored by
University of Colorado, Colorado Springs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PreDiabetes

Eligibility Criteria

50 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • (1) no unresolved health conditions (e.g. if high blood pressure is present it is under control due to diet and/or medications) and no diagnosis of type 2 diabetes;
  • (2) non-smoking status;
  • (3) no regular history of flaxseed or flaxseed oil supplement or fish oil supplement intake;
  • (4) no regular history of sunflower seed intake (1/8 cup < 1 time per week); fish intake (< 12 ounces of fish/week); and soy intake (1 serving of soy < 3 times per week; 1 serving of soy equals 3 oz. tofu, 8 oz. soy milk, ¼ c. soy nuts or ½ c. edamame);
  • (5) willingness to follow study protocol, scheduling, and testing location;
  • (6) body mass index (BMI) of 25-34.9 kg/m2;
  • (7) men or postmenopausal women (no menstrual cycle for > 6 months; women who have had a hysterectomy are eligible for participation) ages 50-65 years;
  • (8) fasting glucose value of > 100 and < 126 mg/dL.

Exclusion Criteria:

  • (1) unresolved health conditions or diagnosis of type 2 diabetes;
  • (2) smokes;
  • (3) regular history of flaxseed or flaxseed oil supplement or fish oil supplement intake;
  • (4) regular history of sunflower seed intake (1/8 cup < 1 time per week); fish intake (< 12 ounces of fish/week); and soy intake (1 serving of soy < 3 times per week; 1 serving of soy equals 3 oz. tofu, 8 oz. soy milk, ¼ c. soy nuts or ½ c. edamame);
  • (5) unwillingness to follow study protocol, scheduling, and testing location;
  • (6) body mass index (BMI) less than 25 or greater than 34.9 kg/m2;
  • (7) premenopausal women;
  • (8) men or postmenopausal women less than 50 or greater than 65 years of age;
  • (9) fasting glucose value of less than 100 or greater than 126 mg/dL.

Sites / Locations

  • University of Colorado Colorado Springs
  • University of Montana

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

Flaxseed High Dose

Flaxseed Low Dose

Flaxseed control

Arm Description

Outcomes

Primary Outcome Measures

Fasting glucose
Fasting insulin
Fasting fructosamine

Secondary Outcome Measures

C-reactive protein
interleukin 6
adiponectin

Full Information

First Posted
September 25, 2012
Last Updated
September 27, 2012
Sponsor
University of Colorado, Colorado Springs
search

1. Study Identification

Unique Protocol Identification Number
NCT01698112
Brief Title
Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?
Official Title
Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
June 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Colorado, Colorado Springs

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This project is a clinical intervention trial that will determine the role of a functional food, flaxseed, on the control of blood glucose levels in people with pre-diabetes. People with pre-diabetes have high blood glucose levels since their cells do not respond to insulin as they should. Over time, people with pre-diabetes may progress to type 2 diabetes and have increased risk for heart and kidney diseases. Although the long-term complications associated with type 2 diabetes are well-recognized, clinicians and researchers are now realizing that some long-term damage to the body, especially the heart and circulatory system, may already be occurring during pre-diabetes. Consequently, clinicians are recognizing that glucose control, through diet, exercise and, if necessary, medications, is as important for people with pre-diabetes as it is for people with type 2 diabetes. Standard treatments for pre-diabetes are glucose control through diet, exercise, and drugs. A possible treatment that could be added to the standard treatments is intake of flaxseed. Few studies have looked at the effect of flaxseed intake on glucose control and those that have enrolled people with type 2 diabetes. To date, no studies have reported flaxseed's affect on controlling blood glucose in people with pre-diabetes. Therefore, more research is needed to determine if flaxseed is an effective means of controlling glucose levels in people with pre-diabetes. This study will help determine whether or not eating modest amounts of flaxseed every day will improve blood glucose and insulin levels in overweight or obese men and postmenopausal women with pre-diabetes. It will also show if flaxseed intake will reduce the degree of inflammation they are experiencing. If flaxseed consumption does help control blood glucose levels in people with pre-diabetes and reduce the degree of inflammation they are experiencing, it may help prevent or delay their progression to type 2 diabetes.
Detailed Description
Pre-diabetes is characterized by hyperglycemia due to ineffective insulin or 'insulin resistance'. Over time, people with pre-diabetes may progress to type 2 diabetes and experience complications including cardiovascular and peripheral vascular disease, hyperlipidemia, retinopathy, neuropathy, and/or nephropathy. Conventional interventions for pre-diabetes are glucose control through diet, exercise, and, if necessary, medications. An efficient but still uncommon adjunct intervention is flaxseed supplementation. Since few studies have examined the affect of flaxseed supplementation on type 2 diabetes and to date, no studies have reported flaxseed's influence on glycemic control in individuals with pre-diabetes, additional research is warranted. The objective of this study is to determine the affect of consuming flaxseed on fasting plasma glucose, insulin, fructosamine, adiponectin, fatty acid concentrations, serum interleukin-6 (hs-IL-6), C-reactive protein (hs-CRP), and urinary lignan excretion in overweight or obese men and postmenopausal women with pre-diabetes. This research will provide data for the strength of the relationship between regular flaxseed intake and biomarkers for pre-diabetes and glycemic control as well as adiponectin values and markers of inflammation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreDiabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Flaxseed High Dose
Arm Type
Experimental
Arm Title
Flaxseed Low Dose
Arm Type
Experimental
Arm Title
Flaxseed control
Arm Type
No Intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Flaxseed High Dose
Intervention Description
26 gram flaxseed intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Flaxseed Low Dose
Intervention Description
13 grams flaxseed
Primary Outcome Measure Information:
Title
Fasting glucose
Time Frame
beginning and end of each 12-week intervention (start of 1st week and end of 12th week)
Title
Fasting insulin
Time Frame
beginning and end of each 12-week intervention (start of 1st week and end of 12th week)
Title
Fasting fructosamine
Time Frame
beginning and end of each 12-week intervention (start of 1st week and end of 12th week)
Secondary Outcome Measure Information:
Title
C-reactive protein
Time Frame
beginning and end of each 12-week intervention (start of 1st week and end of 12th week)
Title
interleukin 6
Time Frame
beginning and end of each 12-week intervention (start of 1st week and end of 12th week)
Title
adiponectin
Time Frame
beginning and end of each 12-week intervention (start of 1st week and end of 12th week)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (1) no unresolved health conditions (e.g. if high blood pressure is present it is under control due to diet and/or medications) and no diagnosis of type 2 diabetes; (2) non-smoking status; (3) no regular history of flaxseed or flaxseed oil supplement or fish oil supplement intake; (4) no regular history of sunflower seed intake (1/8 cup < 1 time per week); fish intake (< 12 ounces of fish/week); and soy intake (1 serving of soy < 3 times per week; 1 serving of soy equals 3 oz. tofu, 8 oz. soy milk, ¼ c. soy nuts or ½ c. edamame); (5) willingness to follow study protocol, scheduling, and testing location; (6) body mass index (BMI) of 25-34.9 kg/m2; (7) men or postmenopausal women (no menstrual cycle for > 6 months; women who have had a hysterectomy are eligible for participation) ages 50-65 years; (8) fasting glucose value of > 100 and < 126 mg/dL. Exclusion Criteria: (1) unresolved health conditions or diagnosis of type 2 diabetes; (2) smokes; (3) regular history of flaxseed or flaxseed oil supplement or fish oil supplement intake; (4) regular history of sunflower seed intake (1/8 cup < 1 time per week); fish intake (< 12 ounces of fish/week); and soy intake (1 serving of soy < 3 times per week; 1 serving of soy equals 3 oz. tofu, 8 oz. soy milk, ¼ c. soy nuts or ½ c. edamame); (5) unwillingness to follow study protocol, scheduling, and testing location; (6) body mass index (BMI) less than 25 or greater than 34.9 kg/m2; (7) premenopausal women; (8) men or postmenopausal women less than 50 or greater than 65 years of age; (9) fasting glucose value of less than 100 or greater than 126 mg/dL.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea Hutchins, PhD
Organizational Affiliation
University of Colorado, Colorado Springs
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Colorado Springs
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80918
Country
United States
Facility Name
University of Montana
City
Missoula
State/Province
Montana
ZIP/Postal Code
59812
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?

We'll reach out to this number within 24 hrs